The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study.
Pascal Hammel
Honoraria - Roche
Florence Huguet
Honoraria - Roche
Jean-Luc Van Laethem
No relevant relationships to disclose
David Goldstein
No relevant relationships to disclose
Bengt Glimelius
No relevant relationships to disclose
Pascal Artru
Consultant or Advisory Role - Roche
Honoraria - Roche
Ivan Borbath
No relevant relationships to disclose
Olivier Bouche
Consultant or Advisory Role - Roche
Jenny Shannon
No relevant relationships to disclose
Thierry André
Consultant or Advisory Role - Roche
Honoraria - Roche
Laurent Mineur
No relevant relationships to disclose
Benoist Chibaudel
No relevant relationships to disclose
Franck Bonnetain
No relevant relationships to disclose
Christophe Louvet
No relevant relationships to disclose